Background: An issue related to the terms of assignment of genetically engineered biological agents to patients with juvenile idiopathic arthritis (JIA) still remains debatable in pediatric rheumatology. Objective: Our aim was to evaluate the efficacy and safety of etanercept therapy in early and late JIA without systemic manifestations. Methods: An observational comparative study. The participants were divided into 2 groups. Patients of the treatment group (n = 98) - with early arthritis (lasting less than 2 years), and patients of the control group (n = 99) - with late arthritis (lasting more than 2 years). All children received etanercept in a dose of 0.4 mg/kg body weight 2 times per week subcutaneously. The efficacy of the therapy was evaluated for 3 years using the criteria of the American College of Rheumatology (ACRpedi), remission criteria by C. Wallace and JADAS71 index. Results: Total number of patients with JIA under the study is 197. After 6 months, the improvement according to the ACRpedi criteria 30/50/70 was recorded in 97/97/91% and 98/96/88%, and after 1 year - in 100/100/99% and 99/94/92% of patients with early and late arthritis, respectively. The efficacy of etanercept according to criteria by C. Wallace and JADAS71 index in early arthritis was higher than in late arthritis within 2 years of observation. Conclusion: Etanercept is more effective in early JIA than in late JIA without systemic manifestations.
Bzarova, T. M., Alexeeva, E. I., Valieva, S. I., Denisova, R. V., Isaeva, K. B., Chistyakova, E. G., … Taibulatov, N. I. (2015). Evaluation of Efficacy and Safety of Etanercept Therapy in Patients with Early and Late Juvenile Idiopathic Arthritis without Systemic Manifestations. Current Pediatrics, 14(4), 489. https://doi.org/10.15690/vsp.v14.i4.1388